Compared to other GLP-1 receptor agonists, semaglutide outperformed dulaglutide and exenatide in weight loss and glycemic control, as shown by Devries et al. and Pratley et al., indicating its potential as a preferred choice for obesity management, especially in patients with T2DM [23,25]. This evidence concerns the gene GLP1R and obesity disorder.